

## Formulary Adherence Checklist for NICE Technology Appraisals About Medicines



Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

Milton Keynes Health Economy

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. **Version 20 March 2018**

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

| Technology appraisal (TA)<br>Titles are hyperlinks to full guidance   | Date of TA Release | Availability of medicine for NHS patients with this medical condition, as indicated by NICE   | Adherence of local formulary to NICE |                                 |                                      |                             |  |
|---|--------------------|---|--------------------------------------|---------------------------------|--------------------------------------|-----------------------------|--|
|   |                    |   | Yes<br>(mark 'x' if applicable)      | N/A<br>(mark 'x' if applicable) | Date of local decision<br>(DD/MM/YY) | Time to implement<br>(days) | Notes (e.g. rationale, method of making available)   |
| <b>2018/2019</b>  |                    |   |                                      |                                 |                                      |                             |  |
| <a href="#">Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)</a> | 04/07/2018         | Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy  | x                                    |                                 | 25/07/2018                           | 21                          | Not recommended  |
| <a href="#">Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)</a>   | 04/07/2018         | Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults  | x                                    |                                 | 25/07/2018                           | 21                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)</a>           | 04/07/2018         | Niraparib is recommended for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based | x                                    |                                 | 25/07/2018                           | 21                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)</a>   | 27/06/2018         | Interferon beta-1a is recommended as an option for treating multiple sclerosis  | x                                    |                                 | 25/07/2018                           | 28                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)</a>   | 13/06/2018         | Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults         | x                                    |                                 | 25/07/2018                           | 42                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)</a>        | 13/06/2018         | Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy   | x                                    |                                 | 25/07/2018                           | 42                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)</a>   | 13/06/2018         | Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease   | x                                    |                                 | 25/07/2018                           | 42                          | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |

|  |            |  |         |         |            |                                      |  |
|--|------------|--|---------|---------|------------|--------------------------------------|--|
| <a href="#">Midostaurin for untreated acute myeloid leukaemia (TA523)</a>  | 13/06/2018 | Midostaurin is recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with  | x       |         | 25/07/2018 | 42                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)</a> | 13/06/2018 | Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable                    | x       |         | 25/07/2018 | 42                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Guselkumab for treating moderate to severe plaque psoriasis (TA521)</a>  | 13/06/2018 | Guselkumab is recommended as an option for treating plaque psoriasis in adults   | x       |         | 25/07/2018 | 42                                   | CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements  |
| <a href="#">Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)</a>                   | 16/04/2018 | Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour), | x       |         | 23/05/2018 | 37                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)</a>    | 25/04/2018 | Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy                            | x       |         | 23/05/2018 | 28                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Tocilizumab for treating giant cell arteritis (TA518)</a>  | 18/04/2018 | Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults  | x       |         | 23/05/2018 | 35                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
| <a href="#">Avelumab for treating metastatic Merkel cell carcinoma (TA517)</a>   | 11/04/2018 | <b>Avelumab</b> is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.   | x       |         | 23/05/2018 | 42                                   | NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements |
|  |            |  | % "Yes" | % "N/A" | -          | <b>Average implement time (days)</b> |  |
| <b>Adherence statistics for 2017-18</b>  |            |  | 100%    | 0%      |            | <b>37</b>                            |  |